Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Winters, Mark A ^a,b   Lloyd, Robert M ^c   Shafer, Robert W ^b   Kozal, Michael J ^d,e   Miller, Michael D ^f   Holodniy, Mark ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Research ThinkTank Inc ^*  (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELVITEGRAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMPLICON; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CLONE; DRUG TREATMENT FAILURE; GENE MUTATION; GENETIC RECOMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE; VIRUS STRAIN;

EID: 84864007971     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040514     Document Type: Article

References (54)

1. Ingale KB, Bhatia MS, (2011) HIV-1 integrase inhibitors: a review of their chemical development. Antivir Chem Chemother 22: 95-105.
2. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, et al. (2010) Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 50: 605-612.
3. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, et al. (2009) Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374: 796-806.
4. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, et al. (2011) Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis.
5. Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, et al. (2011) Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25: F7-12.
6. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, et al. (2010) Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 201: 814-822.
7. Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, et al. (2012) Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 12: 27-35.
8. Rangel HR, Garzaro D, Fabbro R, Martinez N, Ossenkop J, et al. (2010) Absence of primary integrase resistance mutations in HIV type 1-infected patients in Venezuela. AIDS Res Hum Retroviruses 26: 923-926.
9. Varghese V, Liu TF, Rhee SY, Libiran P, Trevino C, et al. (2010) HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses 26: 1323-1326.
10. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW, (2011) HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 203: 1204-1214.
11. Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, et al. (2009) Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 63: 795-804.
12. Hu Z, Kuritzkes DR, (2010) Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 55: 148-155.
13. Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, et al. (2010) Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr 54: 389-393.
14. Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, et al. (2010) Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J Antimicrob Chemother 65: 425-433.
15. Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, et al. (2010) Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clin Microbiol Infect 17: 928-934.
16. Ferns RB, Kirk S, Bennett J, Cook PM, Williams I, et al. (2009) The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 23: 2159-2164.
17. Codoner FM, Pou C, Thielen A, Garcia F, Delgado R, et al. (2010) Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res 88: 281-286.
18. Liu J, Miller MD, Danovich RM, Vandergrift N, Cai F, et al. (2011) Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother 55: 1114-1119.
19. Jordan MR, Kearney M, Palmer S, Shao W, Maldarelli F, et al. (2010) Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations. J Virol Methods 168: 114-120.
20. Vandenbroucke I, Eygen VV, Rondelez E, Vermeiren H, Baelen KV, et al. (2008) Minor Variant Detection at Different Template Concentrations in HIV-1 Phenotypic and Genotypic Tropism Testing. Open Virol J 2: 8-14.
21. Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, et al. (2009) Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 23: 455-460.
22. Mukherjee R, Jensen ST, Male F, Bittinger K, Hodinka RL, et al. (2011) Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS 25: 1951-1959.
23. da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, et al. (2010) HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 65: 1262-1269.
24. Baldanti F, Paolucci S, Gulminetti R, Brandolini M, Barbarini G, et al. (2010) Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J Med Virol 82: 116-122.
25. Lataillade M, Chiarella J, Yang R, Uy J, DeGrosky M, et al. (2011) Prevalence and clinical significance of raltegravir (RAL) and atazanavir (ATV) resistance mutations by ultra-deep sequencing (UDS) in HIV-infected antiretroviral-naive subjects in the SPARTAN study. Antivir Ther 16: A34.
26. McColl DJ, Fransen S, Gupta S, Parkin N, Margo N, et al. (2007) Resistance and Cross-Resistance to First Generation Integrase Inhibitors: Insights from a Phase 2 Study of Elvitegravir (GS-9137). Antiviral Ther 12: S11.
27. Waters J, Margot N, Hluhanich R, Svarovskaia J, Harris J, et al. (2009) Evolution of resistance to the HIV integrase inhibitor (INI) elvitegravir can involve genotypic switching among primary INI resistance patterns. Antivir Ther 14: A137.
28. Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, et al. (2009) Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 83: 11440-11446.
29. Goodman DD, Hluhanich R, Waters J, Margot NA, Fransen S, et al. (2008) Integrase inhibitor resistance involves complex interactions amont primary and secondary resistance mutations: a novel mutation L68V/I associates with E92Q and increases resistance. Antivir Ther 13 A15.
30. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, et al. (2008) Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 82: 3952-3970.
31. Meyerhans A, Vartanian JP, Wain-Hobson S, (1990) DNA recombination during PCR. Nucleic Acids Res 18: 1687-1691.
32. Yang YL, Wang G, Dorman K, Kaplan AH, (1996) Long polymerase chain reaction amplification of heterogeneous HIV type 1 templates produces recombination at a relatively high frequency. AIDS Res Hum Retroviruses 12: 303-306.
33. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, et al. (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 68: 1660-1666.
34. Towler WI, Church JD, Eshleman JR, Fowler MG, Guay LA, et al. (2008) Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq). AIDS Res Hum Retroviruses 24: 1209-1213.
35. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, et al. (1992) Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 165: 105-110.
36. Kavlick MF, Wyvill K, Yarchoan R, Mitsuya H, (1998) Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J Infect Dis 177: 1506-1513.
37. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, et al. (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 2: 760-766.
38. Soriano V, de Mendoza C, (2002) Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. HIV Clin Trials 3: 249-257.
39. Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, et al. (2010) Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 5: e11345.
40. Mbisa JL, Gupta RK, Kabamba D, Mulenga V, Kalumbi M, et al. (2011) The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains. Retrovirology 8: 31.
41. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43: 406-413.
42. Gonzales MJ, Johnson E, Dupnik KM, Imamichi T, Shafer RW, (2003) Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing. J Acquir Immune Defic Syndr 34: 398-402.
43. Buzon MJ, Dalmau J, Puertas MC, Puig J, Clotet B, et al. (2009) The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. AIDS 24: 17-25.
44. Reigadas S, Anies G, Masquelier B, Calmels C, Stuyver LJ, et al. (2010) The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions. PLoS One 5: e10311.
45. Rodenburg CM, Li Y, Trask SA, Chen Y, Decker J, et al. (2001) Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses 17: 161-168.
46. Shi B, Kitchen C, Weiser B, Mayers D, Foley B, et al. (2010) Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy. Virology 404: 5-20.
47. Rockstroh JK, Teppler H, Zhao J, Sklar P, Miller MD, et al. (2011) Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. AIDS 25: 1365-1369.
48. Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, et al. (2011) Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol 83: 751-759.
49. Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, et al. (2011) The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother 66: 2827-2830.
50. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, et al. (2009) Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 199: 693-701.
51. Fang G, Zhu G, Burger H, Keithly JS, Weiser B, (1998) Minimizing DNA recombination during long RT-PCR. J Virol Methods 76: 139-148.
52. Shafer RW, (2006) Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194: S51-58.
53. Huson DH, Bryant D, (2006) Application of phylogenetic networks in evolutionary studies. Mol Biol Evol 23: 254-267.
54. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, et al. (1999) Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 73: 152-160.